

# Evolve Global Healthcare Enhanced Yield Fund

December 31, 2024

Annual Management Report of Fund Performance

This annual management report of fund performance contains financial highlights but does not contain the complete annual financial statements of the investment fund. You can get a copy of the annual financial statements at your request, and at no cost, by calling 1-844-370-4884, by writing to us at Evolve Funds, 40 King Street West, Suite 3404, Toronto, ON, M5H 3Y2 or by visiting our website at [www.evolveetfs.com](http://www.evolveetfs.com) or SEDAR at [www.sedar.com](http://www.sedar.com). You may also contact us using one of these methods to request a copy of the investment fund's proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure.

# Evolve Global Healthcare Enhanced Yield Fund

December 31, 2024

---

## Investment Objective and Strategies

---

The Evolve Global Healthcare Enhanced Yield Fund (the "Fund") seeks to replicate, to the extent reasonably possible before fees and expenses, the performance of the Solactive Global Healthcare 20 Index Canadian Dollar Hedged, or any successor thereto, while mitigating downside risk. The Fund invests primarily in the equity constituents of the Solactive Global Healthcare 20 Index Canadian Dollar Hedged, or any successor thereto, while writing covered call options on up to 33% of the portfolio securities, at the discretion of the portfolio manager. The level of covered call option writing may vary based on market volatility and other factors.

## Risk

---

There were no changes to the Fund over the period of this report that materially affected the level of risk associated with an investment in the Fund. Prospective investors should read the Fund's most recent prospectus and consider the description of risks contained therein.

## Results of Operations

---

For the year ended December 31, 2024, the Unhedged ETF Units returned 9.9% versus the Solactive Global Healthcare 20 Index NTR return of 11.2%. The Hedged ETF Units returned 2.3% versus the Solactive Global Healthcare 20 Index Canadian Dollar Hedged return of 1.3%. The US Dollar Unhedged ETF Units returned 1.3% versus the Solactive Global Healthcare 20 Index Canadian Dollar Hedged return of 1.3%. The Hedged Class A Mutual Fund Units returned 1.1% and the Hedged Class F Mutual Fund Units returned 2.2% versus the Solactive Global Healthcare 20 Index Canadian Dollar Hedged return of 1.3%. For a discussion of the relative performance of the Fund as compared to the respective Index, please refer to the "Annual Compound Return" section in the "Management Discussion of Fund Performance". The Fund's net assets were \$277.2MM as at December 31, 2024.

For the period ended December 31, 2024, the Fund generated an increase (decrease) in net assets attributable to holders of redeemable units from operations of \$10,259,557. This compares to \$9,724,679 for the period ended December 31, 2023. The Fund distributed \$27,899,148 to unitholders during the year (2023 - \$24,189,824). The decision to make distributions exceeding earnings was made by Evolve Funds Group Inc. (the "Manager"), due to the following factors:

The Funds' Declaration of Trust requires that sufficient amounts be paid or made payable each year so that the Funds are not liable for any non-refundable income tax under Part I of the Tax Act.

Amounts included in the calculation of the Fund's net income and net realized capital gains for a taxation year may encompass amounts that have not yet been received by the Fund.

The Manager believes that maintaining regular and stable distributions is vital to meet unitholder expectations and retain investor confidence. Consequently, distribution rates are only adjusted in response to material changes.

The Manager believes that a full business cycle is required for a comprehensive evaluation of results.

The Manager holds a strong conviction in the Fund's investment objective and its future growth prospects.

## Portfolio Manager Commentary

---

The healthcare industry experienced a year of conflicting trends in 2024, with strong performance in the first half of the year driven by the incredible success of weight loss drugs, followed by mixed results in the latter half due to macroeconomic and political uncertainties.

Weight loss drugs, particularly GLP-1 receptor agonists, emerged as a dominant theme in the healthcare industry during the period. Eli Lilly led the charge with Mounjaro, which was initially approved as a treatment for diabetes, but its use case was later expanded to treat obesity as well. This fueled remarkable sales growth as demand soared for the drug, resulting in several periods of increased revenues for the pharmaceutical company. Novo Nordisk also thrived with its GLP-1 products, Wegovy and Ozempic, cementing their dominance in the fight against chronic conditions such as obesity and cardiovascular disease.

Intuitive Surgical also had an exceptional year, supported by increased adoption of its da Vinci surgical systems and investor interest in artificial intelligence (AI) assisted technologies. The company's advancements in robotic-assisted surgery, coupled with growing demand for cost-efficient and precise healthcare, drove strong revenue growth throughout the period<sup>1</sup>. Similarly, Boston Scientific performed well, driven by increased sales of its innovative cardiovascular devices such as WATCHMAN FLX and growth in its interventional cardiology segment bolstering results<sup>2</sup>.

# Evolve Global Healthcare Enhanced Yield Fund

December 31, 2024

---

The US election added volatility to the sector, as President-Elect Donald Trump indicated his intentions to appoint Robert F. Kennedy Jr. as the head of the Department of Health and Human Services. Kennedy's controversial stance on Big Pharma, including calls for tighter regulation on pharmacy benefit managers (PBMs) and pharmaceutical manufacturers in addition to price caps, sparked investor fears, leading to a selloff in healthcare stocks in the latter half of the year<sup>3</sup>.

Overall, 2024 has been a pivotal year for the healthcare sector, marked by a successful shift from COVID-19 vaccine-focused strategies to weight loss drugs and other groundbreaking healthcare innovations. Despite this progress, evolving political developments have introduced a layer of uncertainty to the industry's outlook for the year ahead.

## Performance Attribution

For the twelve-month period ending December 31, 2024, Intuitive Surgical Inc made the biggest contribution to the Fund, followed by Eli Lilly & Company. By weight, the Fund's largest holdings were Intuitive Surgical Inc, Boston Scientific Corporation, and Stryker Corporation.

(1) <https://www.forbes.com/sites/greatspeculations/2024/09/04/why-is-intuitive-surgical-stock-up-80/>

(2) <https://seekingalpha.com/news/4303450-boston-sci-stock-climbs-on-positive-watchman-flx-data>

(3) <https://www.reuters.com/business/healthcare-pharmaceuticals/europe-vaccine-makers-fall-trump-picks-rfk-jr-lead-top-us-health-agency-2024-11-15/>

## Recent Developments

---

In 2025, trade tensions have escalated as the United States considers imposing new tariffs on key trading partners, including Canada and Mexico, along with broader reciprocal measures on other nations. In response, affected countries may enact retaliatory tariffs, further increasing uncertainty in global trade. These developments have contributed to heightened market volatility and could disrupt global supply chains, particularly impacting trade-sensitive sectors. The duration and full impact of these events remain uncertain, and as such, the financial implications for investments cannot be estimated at this time.

## Related Party Transactions

---

The Manager, a corporation incorporated under the laws of the Province of Ontario, is the trustee, manager, and portfolio advisor of the Fund and is responsible for the day-to-day administration of the Fund. The Fund pays annual management fees to the Manager as consideration for its services. Any management fees paid to the Manager are related party transactions, as the Manager is considered to be a related party to the Fund. The management fees are disclosed in the statements of comprehensive income in the annual financial statements of the Fund and are discussed in greater detail below.

The Fund is permitted to purchase, sell and hold securities of certain issuers that are directly or indirectly related to the Manager. With respect to investment in related issuers, the Manager has relied on the approval that it has received from the Investment Review Committee ("IRC"). The Manager complies with its current policy and procedures regarding investments in related issuers and reports periodically to the IRC.

## Management Fees

The Manager is entitled to an annual management fee of 0.45% of the net asset value of the Hedged, Unhedged and US Dollar Unhedged ETF Units and the Hedged Class F Mutual Fund Units and 1.45% of the net asset value of the Hedged Class A Mutual Fund Units of the Fund, accrued daily and generally paid monthly in arrears. For the year ended December 31, 2024, the Fund incurred \$1,407,731 in management fees. These management fees were received by the Manager for the day-to-day operations of the fund, including managing the portfolio, maintaining portfolio systems used to manage the Fund, maintaining the [www.evolveetfs.com](http://www.evolveetfs.com) website, and providing all other services including marketing and promotion.

# Evolve Global Healthcare Enhanced Yield Fund

December 31, 2024

## Administration Fees

The administration fees are calculated based on 0.15% per annum of the average daily net asset value of the Fund. The fees are accrued daily and are generally paid monthly. For the year ended December 31, 2024, the Fund incurred \$469,365 in administration fees. These administration fees were received by the Manager for the following operating expenses of the Fund including but not limited to: mailing and printing expenses for periodic reports to unitholders; fees payable to the index provider, Registrar and Transfer Agent and Custodian; any reasonable out of pocket expenses incurred by the Manager or its agents in connection with their ongoing obligations to the Fund; IRC committee member fees and expenses in connection with the IRC; expenses related to compliance with NI 81-107; fees and expenses relating to voting of proxies by a third party; insurance coverage for the members of the IRC; fees payable to the auditors and legal advisors of the Fund; regulatory filing, stock exchange and licensing fees and CDS fees; costs and expenses of complying with all applicable laws, regulations and policies, including expenses and costs incurred in connection with the continuous public filing requirements such as permitted prospectus preparation and filing expenses; and legal, accounting and audit fees and fees and expenses of the Trustee, Custodian and Manager which are incurred in respect of matters not in the normal course of the Fund's activities. The administration fee paid to the Manager by the Fund may, in any particular period, be less than or exceed the operating expenses that the Manager incurs for the Fund.

## Financial Highlights

The following tables show selected key financial information about the Fund and are intended to help readers understand the Fund's financial performance for the period indicated.

### The Fund's Net Assets Per Unit<sup>1</sup>

For the periods ended:	December 31, 2024 (\$)	December 31, 2023 (\$)	December 31, 2022 (\$)	December 31, 2021 (\$)	December 31, 2020 (\$)
<b>Unhedged ETF Units - Net Assets per Unit</b>					
Net Assets per Unit, beginning of period	23.80	24.87	25.48	23.16	22.71
<b>Increase (decrease) from operations:</b>					
Total revenue	0.45	0.81	0.75	0.54	0.65
Total expenses	(0.25)	(0.29)	(0.26)	(0.24)	(0.27)
Realized gains (losses)	1.61	2.10	(0.46)	0.66	0.35
Unrealized gains (losses)	0.70	(1.72)	1.18	2.90	0.42
<b>Total increase (decrease) from operations<sup>2</sup></b>	<b>2.51</b>	<b>0.90</b>	<b>1.21</b>	<b>3.86</b>	<b>1.15</b>
<b>Distributions:</b>					
From dividends	(0.32)	(0.39)	(0.47)	(0.28)	(0.25)
From capital gains	(0.75)	(0.41)	-	(0.87)	(0.75)
Return of capital	(1.15)	(1.12)	(1.33)	(0.38)	(0.50)
<b>Total annual distributions<sup>3</sup></b>	<b>(2.22)</b>	<b>(1.92)</b>	<b>(1.80)</b>	<b>(1.53)</b>	<b>(1.50)</b>
<b>Net Assets per Unit, end of period</b>	<b>23.97</b>	<b>23.80</b>	<b>24.87</b>	<b>25.48</b>	<b>23.16</b>
<b>Hedged ETF Units - Net Assets per Unit</b>					
Net Assets per Unit, beginning of period	20.79	21.88	23.59	21.14	21.14
<b>Increase (decrease) from operations:</b>					
Total revenue	0.35	0.72	0.69	0.46	0.55
Total expenses	(0.21)	(0.25)	(0.24)	(0.23)	(0.23)
Realized gains (losses)	(0.07)	1.89	(1.18)	0.19	1.17
Unrealized gains (losses)	0.23	(1.61)	1.10	3.70	0.53
<b>Total increase (decrease) from operations<sup>2</sup></b>	<b>0.30</b>	<b>0.75</b>	<b>0.37</b>	<b>4.12</b>	<b>2.02</b>
<b>Distributions:</b>					
From dividends	(0.26)	(0.34)	(0.42)	(0.23)	(0.34)
From capital gains	(0.73)	(0.44)	-	(0.88)	(0.69)
Return of capital	(1.11)	(1.14)	(1.38)	(0.42)	(0.47)
<b>Total annual distributions<sup>3</sup></b>	<b>(2.10)</b>	<b>(1.92)</b>	<b>(1.80)</b>	<b>(1.53)</b>	<b>(1.50)</b>
<b>Net Assets per Unit, end of period</b>	<b>19.28</b>	<b>20.79</b>	<b>21.88</b>	<b>23.59</b>	<b>21.14</b>

# Evolve Global Healthcare Enhanced Yield Fund

December 31, 2024

## The Fund's Net Assets Per Unit<sup>1</sup> (cont'd)

For the periods ended:	December 31, 2024 (\$)	December 31, 2023 (\$)	December 31, 2022 (\$)	December 31, 2021 (\$)	December 31, 2020 (\$)
<b>US Dollar Unhedged ETF Units - Net Assets per Unit<sup>4</sup></b>					
Net Assets per Unit, beginning of period	27.20	28.82	29.80	27.21	26.91
<b>Increase (decrease) from operations:</b>					
Total revenue	0.54	0.94	0.85	0.59	0.78
Total expenses	(0.29)	(0.34)	(0.30)	(0.28)	(0.33)
Realized gains (losses)	1.72	2.45	(0.42)	0.76	0.38
Unrealized gains (losses)	1.34	(2.06)	2.06	3.56	0.70
<b>Total increase (decrease) from operations<sup>2</sup></b>	<b>3.31</b>	<b>0.99</b>	<b>2.19</b>	<b>4.63</b>	<b>1.53</b>
<b>Distributions:</b>					
From dividends	(0.35)	(0.45)	(0.56)	(0.31)	(0.33)
From capital gains	(1.03)	(0.59)	-	(1.09)	(0.99)
Return of capital	(1.50)	(1.55)	(1.99)	(0.52)	(0.69)
<b>Total annual distributions<sup>3</sup></b>	<b>(2.88)</b>	<b>(2.59)</b>	<b>(2.55)</b>	<b>(1.92)</b>	<b>(2.01)</b>
<b>Net Assets per Unit, end of period</b>	<b>27.04</b>	<b>27.20</b>	<b>28.82</b>	<b>29.80</b>	<b>27.21</b>
<b>Hedged Class A - Net Assets per Unit</b>					
Net Assets per Unit, beginning of period	18.08	19.48	21.48	19.59	19.90
<b>Increase (decrease) from operations:</b>					
Total revenue	0.27	0.63	0.61	0.45	0.26
Total expenses	(0.39)	(0.43)	(0.44)	(0.44)	(0.20)
Realized gains (losses)	(0.16)	1.64	(1.06)	0.36	0.62
Unrealized gains (losses)	0.03	(1.44)	(0.13)	2.97	0.08
<b>Total increase (decrease) from operations<sup>2</sup></b>	<b>(0.25)</b>	<b>0.40</b>	<b>(1.02)</b>	<b>3.34</b>	<b>0.76</b>
<b>Distributions:</b>					
From dividends	-	(0.10)	(0.20)	(0.03)	(0.31)
From capital gains	(0.81)	(0.51)	-	(1.06)	(0.21)
Return of capital	(1.29)	(1.31)	(1.60)	(0.44)	(0.10)
<b>Total annual distributions<sup>3</sup></b>	<b>(2.10)</b>	<b>(1.92)</b>	<b>(1.80)</b>	<b>(1.53)</b>	<b>(0.62)</b>
<b>Net Assets per Unit, end of period</b>	<b>16.30</b>	<b>18.08</b>	<b>19.48</b>	<b>21.48</b>	<b>19.59</b>
<b>Hedged Class F - Net Assets per Unit</b>					
Net Assets per Unit, beginning of period	19.19	20.32	22.05	19.85	19.89
<b>Increase (decrease) from operations:</b>					
Total revenue	0.28	0.66	0.63	0.41	0.26
Total expenses	(0.20)	(0.21)	(0.22)	(0.21)	(0.10)
Realized gains (losses)	(0.14)	1.62	(1.21)	0.02	0.35
Unrealized gains (losses)	(0.04)	(0.71)	1.28	3.86	0.29
<b>Total increase (decrease) from operations<sup>2</sup></b>	<b>(0.10)</b>	<b>1.36</b>	<b>0.48</b>	<b>4.08</b>	<b>0.80</b>
<b>Distributions:</b>					
From dividends	(0.22)	(0.28)	(0.39)	(0.21)	(0.22)
From capital gains	(0.73)	(0.41)	-	(0.87)	(0.25)
Return of capital	(1.15)	(1.23)	(1.41)	(0.45)	(0.16)
<b>Total annual distributions<sup>3</sup></b>	<b>(2.10)</b>	<b>(1.92)</b>	<b>(1.80)</b>	<b>(1.53)</b>	<b>(0.63)</b>
<b>Net Assets per Unit, end of period</b>	<b>17.64</b>	<b>19.19</b>	<b>20.32</b>	<b>22.05</b>	<b>19.85</b>

1 This information is derived from the Fund's audited annual financial statements as at December 31, 2024, 2023, 2022, 2021, and 2020. The Unhedged and Hedged ETF Units effectively began operations on October 23, 2017, the US Dollar Unhedged ETF Units effectively began operations on November 26, 2019, and the Hedged Class A and F Mutual Fund Units effectively began operations on July 7, 2020.

2 Net assets and distributions are based on the actual number of units outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of units outstanding over the period.

3 Distributions were paid in cash or reinvested in additional units of the Fund, or both. Actual distributions may vary slightly owing to rounding.

4 Per unit figures are stated in CAD equivalent.

# Evolve Global Healthcare Enhanced Yield Fund

December 31, 2024

## The Fund's Ratios/Supplemental Data

For the periods ended:	December 31, 2024	December 31, 2023	December 31, 2022	December 31, 2021	December 31, 2020
<b>Unhedged ETF Units - Ratios/Supplemental Data</b>					
Total Net Asset Value (\$) <sup>5</sup>	41,803,868	45,675,066	41,043,080	40,766,891	37,642,125
Number of units outstanding <sup>5</sup>	1,744,000	1,919,000	1,650,000	1,600,000	1,625,000
Management expense ratio <sup>6</sup>	0.62%	0.68%	0.67%	0.65%	0.68%
Trading expense ratio <sup>7</sup>	0.07%	0.06%	0.06%	0.06%	0.11%
Portfolio turnover rate <sup>8</sup>	68.51%	57.04%	73.30%	44.05%	59.63%
Net Asset Value per unit (\$)	23.97	23.80	24.87	25.48	23.16
Closing market price (\$)	23.98	23.79	24.86	25.51	23.16
<b>Hedged ETF Units - Ratios/Supplemental Data</b>					
Total Net Asset Value (\$) <sup>5</sup>	205,822,647	181,981,672	189,187,745	154,484,891	75,062,124
Number of units outstanding <sup>5</sup>	10,677,996	8,752,996	8,647,996	6,550,000	3,550,000
Management expense ratio <sup>6</sup>	0.65%	0.68%	0.68%	0.67%	0.68%
Trading expense ratio <sup>7</sup>	0.07%	0.06%	0.06%	0.06%	0.11%
Portfolio turnover rate <sup>8</sup>	68.51%	57.04%	73.30%	44.05%	59.63%
Net Asset Value per unit (\$)	19.28	20.79	21.88	23.59	21.14
Closing market price (\$)	19.28	20.79	21.91	23.71	21.16
<b>US Dollar Unhedged ETF Units - Ratios/Supplemental Data</b>					
Total Net Asset Value (\$) <sup>5</sup>	16,928,508	23,830,911	25,970,927	11,919,429	7,483,511
Number of units outstanding <sup>5</sup>	626,038	876,038	901,038	400,000	275,000
Management expense ratio <sup>6</sup>	0.66%	0.68%	0.67%	0.65%	0.70%
Trading expense ratio <sup>7</sup>	0.07%	0.06%	0.06%	0.06%	0.11%
Portfolio turnover rate <sup>8</sup>	68.51%	57.04%	73.30%	44.05%	59.63%
Net Asset Value per unit (\$)	27.04	27.20	28.82	29.80	27.21
Closing market price (\$)	27.05	27.24	28.81	29.85	27.21
<b>Hedged Class A - Ratios/Supplemental Data</b>					
Total Net Asset Value (\$) <sup>5</sup>	1,520,841	1,032,766	1,025,711	1,507,193	1,053,714
Number of units outstanding <sup>5</sup>	93,313	57,122	52,641	70,169	53,793
Management expense ratio <sup>6</sup>	1.80%	1.81%	1.80%	1.81%	1.78%
Trading expense ratio <sup>7</sup>	0.07%	0.06%	0.06%	0.06%	0.11%
Portfolio turnover rate <sup>8</sup>	68.51%	57.04%	73.30%	44.05%	59.63%
Net Asset Value per unit (\$)	16.30	18.08	19.48	21.48	19.59
<b>Hedged Class F - Ratios/Supplemental Data</b>					
Total Net Asset Value (\$) <sup>5</sup>	11,120,540	6,361,584	1,010,940	619,093	197,392
Number of units outstanding <sup>5</sup>	630,567	331,439	49,747	28,074	9,942
Management expense ratio <sup>6</sup>	0.68%	0.68%	0.68%	0.68%	0.67%
Trading expense ratio <sup>7</sup>	0.07%	0.06%	0.06%	0.06%	0.11%
Portfolio turnover rate <sup>8</sup>	68.51%	57.04%	73.30%	44.05%	59.63%
Net Asset Value per unit (\$)	17.64	19.19	20.32	22.05	19.85

5 This information is provided as at December 31, 2024, 2023, 2022, 2021, and 2020.

6 Management expense ratio ("MER") is based on total expenses plus harmonized sales tax (excluding distributions, commissions and other portfolio transaction costs) for the stated period and is expressed as an annualized percentage of daily average net asset value during the period.

7 The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of average daily net assets during the period.

8 The Fund's portfolio turnover rate indicates how actively the Fund's portfolio manager trades its portfolio investments. A portfolio turnover rate of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the period. The higher the Fund's portfolio turnover rate in a period, the greater the trading costs payable by the Fund in the period, and the greater the chance of an investor receiving taxable capital gains in the period. There is not necessarily a relationship between a high turnover rate and the performance of a fund.

# Evolve Global Healthcare Enhanced Yield Fund

December 31, 2024


## Past Performance

The performance information does not take into account sales, redemption, distribution, income taxes payable by any unitholder or other optional charges that, if applicable, would have reduced returns or performance. The performance information shown assumes that all distributions made by the investment fund in the periods shown were reinvested in additional securities of the investment fund. How the Fund has performed in the past does not necessarily indicate how it will perform in the future.


## Year-by-Year Returns

The bar chart below shows the Hedged, Unhedged, US Dollar Unhedged ETF Units', and the Hedged Class A and F Mutual Fund Units' performance for each of the financial years shown. The chart shows, in percentage terms, how much an investment made in the Fund on the first day of each financial period would have grown or decreased by the last day of that financial period.

### LIFE Hedged ETF Units<sup>1</sup>




### LIFE/B Unhedged ETF Units<sup>2</sup>




1 The Hedged ETF Units of the Fund effectively began operations on October 23, 2017.

2 The Unhedged ETF Units of the Fund effectively began operations on October 23, 2017.

### LIFE/U US Dollar Unhedged ETF Units<sup>3</sup>



### Hedged Class A Mutual Fund Units<sup>4</sup>




3 The US Dollar Unhedged ETF Units of the Fund effectively began operations on November 26, 2019. Returns presented based on NAV equivalent in USD.

4 The Hedged Class A Mutual Fund Units of the Fund effectively began operations on July 7, 2020.

# Evolve Global Healthcare Enhanced Yield Fund

December 31, 2024

## Hedged Class F Mutual Fund Units<sup>5</sup>



<sup>5</sup> The Hedged Class F Mutual Fund Units of the Fund effectively began operations on July 7, 2020.

## Annual Compound Return

The table below shows the historical annual compound total return of the Hedged, Unhedged, US Dollar Unhedged ETF Units, and the Hedged Class A and F Mutual Fund Units. The returns are for the period ended December 31, 2024. As a basis of comparison, we have provided the performance of Solactive Global Healthcare 20 Index Canadian Dollar Hedged and Solactive Global Healthcare 20 Index NTR (each of which, an “Index”, and collectively, the “Indices”). The difference in performance of the Hedged, Unhedged, and US Dollar Unhedged ETF Units as well as the Hedged Class A and F Mutual Fund Units relative to the respective Index can be attributed primarily to management and administration fees plus applicable sales taxes, and to portfolio trading. The difference in performance of the US Dollar Unhedged ETF Units relative to the Index can also be attributed to the fact that the Index used is hedged to Canadian Dollars while the US Dollar Unhedged ETF Units of the Fund are unhedged and presented in US Dollars. Furthermore, the difference in performance of the Hedged, Unhedged, US Dollar Unhedged ETF Units and the Hedged Class A and F Mutual Fund Units relative to the respective Index can also be attributed to the implementation of the call writing strategy where the Fund tends to outperform in flat or down markets and underperform during sharp market advances. This performance difference can be seen over the period the calls are written, typically with one to two months to expiry, and then resets when new option positions are established.

The Index used in the table below is different from the Index used in the most recently filed Management Report of Fund Performance for the US Dollar Unhedged ETF Units because the US Dollar denominated version of the Index is no longer available. As a result, the Canadian Dollar Hedged Index is used to reduce the effects of currency exchange rate fluctuations on the performance of the Index.

	Since Inception <sup>1</sup> (%)	1 Year (%)	3 Year (%)	5 Year (%)
Hedged ETF Units	7.2	2.3	2.4	6.6
Solactive Global Healthcare 20 Index Canadian Dollar Hedged <sup>2</sup>	5.8	1.3	0.9	5.0
Unhedged ETF Units	9.7	9.9	6.2	8.9
Solactive Global Healthcare 20 Index NTR <sup>3</sup>	9.7	11.2	6.5	9.5
US Dollar Unhedged ETF Units	7.3	1.3	1.8	6.7
Solactive Global Healthcare 20 Index Canadian Dollar Hedged <sup>2</sup>	5.6	1.3	0.9	5.0
Hedged Class A Mutual Fund Units	5.0	1.1	1.1	N/A
Solactive Global Healthcare 20 Index Canadian Dollar Hedged <sup>2</sup>	5.3	1.3	0.9	N/A
Hedged Class F Mutual Fund Units	6.4	2.2	2.4	N/A



# Evolve Global Healthcare Enhanced Yield Fund

December 31, 2024

	Since Inception <sup>1</sup> (%)	1 Year (%)	3 Year (%)	5 Year (%)
Solactive Global Healthcare 20 Index Canadian Dollar Hedged <sup>2</sup>	5.3	1.3	0.9	N/A

- 1 From inception date of October 23, 2017 for the Hedged and Unhedged ETF Units, from inception date of November 26, 2019 for the US Dollar Unhedged ETF Units, and from inception date of July 7, 2020 for the Hedged Class A and F Mutual Fund Units.
- 2 The Solactive Global Healthcare 20 Index Canadian Dollar Hedged is an Index of Solactive AG and is calculated and distributed by Solactive AG. The Index tracks the performance of the Solactive Global Healthcare 20 Index net total return ("NTR") and hedges the currency exposure to Canadian Dollars on a monthly basis via FX forward contracts. The Index is rebalanced monthly and is denominated in Canadian Dollars.
- 3 The Solactive Global Healthcare 20 Index NTR is an Index of Solactive AG and is calculated and distributed by Solactive AG. The Index provides exposure to the largest global healthcare companies classified under the FactSet Sector Health Technology on an equally-weighted basis. The Index is calculated as a net total return index, is rebalanced quarterly and is denominated in Canadian Dollars.

## Summary of Investment Portfolio

### All Positions

Security	Percentage of Net Asset Value (%)
Intuitive Surgical Inc.	6.1
Boston Scientific Corporation	5.8
Stryker Corporation	5.7
Abbott Laboratories	5.5
AbbVie Inc.	5.2
Merck & Company Inc.	5.1
Pfizer Inc.	5.1
Medtronic PLC	5.1
Roche Holding AG, ADR	5.1
Johnson & Johnson	5.1
Thermo Fisher Scientific Inc.	4.9
Sanofi SA, ADR	4.9
Danaher Corporation	4.8
AstraZeneca PLC, ADR	4.8
Novartis AG, ADR	4.8
Vertex Pharmaceuticals Inc.	4.7
Eli Lilly & Company	4.7
Amgen Inc.	4.5
Novo Nordisk A/S, ADR	4.1
Regeneron Pharmaceuticals Inc.	4.0
<b>Total</b>	<b>100.0</b>

### Industry Allocation

Portfolio by Category	Percentage of Net Asset Value (%)
<b>Equities</b>	
Healthcare	100.0
Derivative Assets	0.1
Derivative Liabilities	(0.0)
Cash and Cash Equivalents	0.6
Other Assets, less Liabilities	(0.7)
<b>Total</b>	<b>100.0</b>

# Evolve Global Healthcare Enhanced Yield Fund

December 31, 2024

---

The summary of Investment Portfolio may change due to the ongoing portfolio transactions of the Fund. Updates are available quarterly by visiting our website at [www.evolveetfs.com](http://www.evolveetfs.com).



**Evolve Global Healthcare Enhanced Yield Fund**